Relatlimab and Nivolumab vs Nivolumab in Previously Untreated Metastatic/Unresectable Melanoma: Overall Survival and Response From RELATIVITY-047 Bookmark

According to MedPage Today, the addition of the drug relatlimab to treatment with nivolumab improved survival for people with advanced melanoma in a clinical trial.

.

Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer Bookmark

Cancer that spreads to the brain is very difficult to treat, especially because of the blood-brain barrier. This article from The ASCO Post describes one promising new treatment.

.

Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification, and Management Bookmark

Written for oncology healthcare professionals, this article from the American Journal of Hematology covers the best new therapies for chronic myelomonocytic leukemia in 2022.

.

Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022 Bookmark

Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

.

10 Years in CLL: Top Advances From 2012-2022 Bookmark

Published by Targeted Therapies in Oncology for healthcare professionals, this article outlines how novel targeted therapies have largely replaced chemotherapy and prolonged life greatly for people with chronic lymphocytic leukemia (CLL).

.

ASCO 2022 Lymphoma In-Depth Bookmark

Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.

.

Lymphoma: New Diagnosis and Current Treatment Strategies Bookmark

Read about personalized and targeted treatments for many types of lymphoma in this scientific review paper written for medical and research professionals and published in the Journal of Clinical Medicine.

.

.

Early Study Finds New Lymphoma Drug Effective Bookmark

According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.

.

‘Unprecedented’ 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly Bookmark

In a remarkable new study, covered in this article from The ASCO Post, 100% of 14 previously untreated patients with mismatch repair-deficient rectal cancer had complete responses—that is, no more signs of their cancer—after treatment with the checkpoint-inhibitor drug dostarlimab (brand name Jemperli) in a phase 2 clinical trial.

.

Colon Cancer Treatment & Management Bookmark

Written for physicians and healthcare professionals, Medscape provides this trustworthy, encyclopedic resource for treating and managing metastatic colorectal cancer.

.